CAMBRIDGE, Mass. (TheStreet) --Vertex Pharmaceuticals (VRTX) CEO Matt Emmens is stepping down in February, just three years after taking the post at the biopharmaceutical firm known best for its recently launched hepatitis C drug Incivek.
Jeff Leiden, a former Abbott (ABT) top executive and current Vertex board member, will take over as Vertex's CEO, the company said in a statement Thursday.
Vertex's CEO swap comes as questions swirl around the company’s future. Incivek was one of the most successful new drug launches in history and helped Vertex reach profitability for the first time. But Incivek's long-term commercial potential is now threatened by newer, more potent hepatitis C therapies working their way towards the market. Most prominently, these new hepatitis C drugs include those Gilead Sciences (GILD) just acquired by paying $11 billion for Pharmasset (VRUS).
As a result, Vertex's stock price, which reached $58 last May right before Incivek was approved, has sunk to around $30 and is down about 14% this year. Vertex is trying to change investor perceptions of the company as one that is solely focused on hepatitis C. Important to this effort to help Vertex diversify will be the expected approval and launch next spring of a new cystic fibrosis drug known as Kalydeco.Emmens came out of retirement from Shire to take the Vertex CEO job and help the company build out a commercial team that could sell Incivek and Kalydeco. Prior to his arrival, Vertex had no approved drugs to sell. "I've been talking to the board about succession since I arrived here," says Emmens, whose three-year employment contract ends in May. "Many CEOs stay too long. I know my skill set and what I was supposed to do at Vertex. Now, it's time to hand over the controls to Jeff." Sanford Bernstein biotech analyst Geoff Porges says many investors who know Vertex well are not surprised Emmens decided to leave once his three-year contract ended. The timing of the transition is a bit earlier than expected, however. "The timing of the announcement may be a bit unsettling to investors given the Incivek questions and the upcoming Kalydeco launch, but Leiden is really smart and it will be to Vertex's advantage to have a guy with a science and business background in charge."
Select the service that is right for you!COMPARE ALL SERVICES
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
- Weekly roundups
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
- Upgrade/downgrade alerts
- Diversified model portfolio of dividend stocks
- Alerts when market news affect the portfolio
- Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
- Real Money + Doug Kass + 15 more Wall Street Pros
- Intraday commentary & news
- Ultra-actionable trading ideas
- 100+ monthly options trading ideas
- Actionable options commentary & news
- Real-time trading community
- Options TV